We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.71% | 1,773.50 | 1,772.00 | 1,772.50 | 1,776.00 | 1,766.00 | 1,770.00 | 6,684,113 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.81 | 72.97B |
Date | Subject | Author | Discuss |
---|---|---|---|
01/2/2023 17:32 | What's rerate ? Will this equate to rise in sp? | alibizzle | |
01/2/2023 17:28 | GSK Final Results. Bottom Line is: MASSIVE increase in net profits before and after tax Profit Before Tax 2021 £3.599B 2022 £5.628B Profit After Tax 2021 £3.516B 2022 £4.921B This, given time, should equate to significant rerate. | netcurtains | |
01/2/2023 17:06 | Those of us who sold on the spike when the litigation clouds lifted can pat ourselves the back. Still mulling whether to put in a limit order to buy back, and if so at what price. AZN has been a great trading share of late - out at 115, back at 97, out at 118.5, back at 110.5. Limit order to sell again at 115. Just set and forget and let market volatility do its stuff. The last repurchase was a bit early in hindsight, but all that matters is to make money on each round trip. What 'fair value' is, search me. I don't really see any compelling reason for saying 90 or 120, or anything in between, so I am using the round trips to get my capital committed down rather than my holding up. | 1knocker | |
01/2/2023 16:18 | Entry to AZN makes no sense now as the share price is already overbought and I suspect gains from here will be small | rikky72 | |
01/2/2023 16:07 | So, does AZN dividend beat GSK? | tradermichael | |
01/2/2023 15:51 | Thee would appear to be no point dismissing your CEO, when it would appear that they and the board are doing all they can. Unfortunately, when 'the market' decides it has a downer on your shareprice, there is nothing anyone can do!! | bothdavis | |
01/2/2023 15:13 | Chachacha Better management too. Superior products. No surprise the outperformance over 1-10 years. | geckotheglorious | |
01/2/2023 14:44 | AZN beats GSK over 1yr, 5yr, 10yr and 20yr for growth. | chachacha | |
01/2/2023 12:44 | Unfortunately, chachacha, the 'darling of the sector' isn't doing too well of late. | thamestrader | |
01/2/2023 12:30 | A bid or the removal of the token female ceo | spoole5 | |
01/2/2023 11:40 | The hedgehogs will never let you forget Zantac,they want revenge to recover their losses | abdullla | |
01/2/2023 11:38 | Absolutely woeful market response , what will it take to light a fire under this appalling ap | alibizzle | |
01/2/2023 11:18 | Forget GSK. AZN is the darling of this sector. | chachacha | |
01/2/2023 10:50 | Yeah I thought we may well push on after some positive news from GSK today but that initial boost seems to have been just that. Time to start thinking about averaging down again rather than being in profit!! | tuftymatt | |
01/2/2023 10:43 | Appalling share price response | tradermichael | |
01/2/2023 10:37 | Next stop 3:45pm | netcurtains | |
01/2/2023 10:20 | Wow that's no nice get back in the bkue | mj19 | |
01/2/2023 10:02 | So far its been 99% of the time blue. | netcurtains | |
01/2/2023 10:00 | I think the Zantac news is more or less all out of the way (bulk of cases). The results were good. No idea if will rise, we will know at two points: 10:30am and 3:45pm (in my opinion). | netcurtains | |
01/2/2023 09:29 | I don't think its going up until the Zantac bad news is out of the way | abdullla | |
01/2/2023 08:14 | Yeah you never can tell how the market will react to news but I would hope we get a challenge of 1500 going off the back of that 👍🏻 | tuftymatt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions